AI Insight: Avanos Medical’s current price of $24.99 significantly exceeds its PERT-weighted fair value of $13.18, implying a 47.2% overvaluation risk. High-confidence DCF analysis projects negative values, contrasting with higher price/sales and analyst target valuations, indicating mixed valuation signals. Financial health shows strong liquidity but zero profitability and efficiency, signaling operational challenges that heighten investment risk despite negligible downside in Monte Carlo scenarios.